Shots:

• The approval is based on the study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older evaluated 3-537 contacts with laboratory-confirmed EVD who received either "immediate" or 21-day "delayed" vaccination with Ervebo
• The study showed that Ervebo was 100% effective in preventing Ebola cases with symptom onset >10 days post-vaccination and no cases of EVD with symptom onset >10 days were observed in the "immediate" cluster group- vs 10 cases of EVD in the 21-day "delayed" cluster group
• Ervebo is the first FDA-approved vaccine targeted for Ebola virus disease (EVD) in adults which is caused by Zaire ebolavirus and has been reviewed under Priority Review and a Tropical Disease Priority Review Voucher also received FDA’s BT designation

Click here to read full press release/ article 

Ref: The US FDA | Image: Merck